Last reviewed · How we verify
SGLT2i+Metformin+Cofrogliptin
This triple-combination therapy reduces blood glucose by inhibiting renal glucose reabsorption (SGLT2i), decreasing hepatic glucose production (metformin), and enhancing insulin secretion (DPP-4 inhibitor cofrogliptin).
This triple-combination therapy reduces blood glucose by inhibiting renal glucose reabsorption (SGLT2i), decreasing hepatic glucose production (metformin), and enhancing insulin secretion (DPP-4 inhibitor cofrogliptin). Used for Type 2 diabetes mellitus.
At a glance
| Generic name | SGLT2i+Metformin+Cofrogliptin |
|---|---|
| Sponsor | Huazhong University of Science and Technology |
| Drug class | SGLT2 inhibitor + Biguanide + DPP-4 inhibitor (fixed-dose combination) |
| Target | SGLT2, mitochondrial complex I, DPP-4 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
SGLT2 inhibitors block sodium-glucose cotransporter 2 in the kidney to promote urinary glucose excretion. Metformin reduces hepatic gluconeogenesis and improves insulin sensitivity. Cofrogliptin, a DPP-4 inhibitor, increases incretin levels to stimulate glucose-dependent insulin secretion. The combination addresses multiple pathophysiologic defects in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Gastrointestinal disturbances
- Hypoglycemia
Key clinical trials
- Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes. (PHASE4)
- Efficacy and Safety Comparison of Cofrogliptin Add-on Versus Metformin Dose-escalation in Type 2 Diabetes Patients Inadequately Controlled With SGLT-2 Inhibitors Plus Low-Dose Metformin:A Multicenter, Open-Label Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: